from Part 4 - Pharmacologic targeting of oncogenic pathways
Published online by Cambridge University Press: 05 February 2015
Introduction, definitions and scope
The estrogen receptor (ER), including estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), mediates the biological effects of estrogen for the development and progression of breast cancer, and it serves as an important diagnostic and therapeutic target for prevention and treatment of breast cancer. Targeted estrogen-receptor therapy is the most successful strategy in breast cancer treatment and prevention. These endocrine therapies include aromatase inhibitors (AIs) indirectly targeting the ER that block the synthesis of estrogen from androgen in peripheral tissues and show efficacy in post-menopausal breast cancer patients. Another direct strategy is to use pure anti-estrogens (also called selective estrogen-receptor down-regulators, SERDs), such as fulvestrant, which have no agonist activity and cause degradation of the ER. Fulvestrant has been approved to treat advanced breast cancer after tamoxifen failure. The most widely used therapy for ER-positive breast cancer is selective estrogen receptor modulators (SERMs), which are synthetic molecules that bind to the ER and can modulate its transcriptional capabilities in different ways in diverse estrogen target tissues. Tamoxifen, the pioneering SERM, is extensively used for targeted therapy of ER-positive breast cancers, and is also approved as the first chemo-preventive agent for lowering breast cancer incidence in high-risk women. The therapeutic and preventive efficacy of tamoxifen was initially proven by a series of experiments in the laboratory that laid the foundation for its clinical use. Unfortunately, use of tamoxifen is associated with de novo and acquired resistance, and some undesirable side effects. The molecular study of resistance provides an opportunity to precisely understand the mechanism of action of SERMs, which may further help in designing new and improved SERMs. Clinical studies demonstrate that another SERM, raloxifene, which is primarily used to treat post-menopausal osteoporosis, is as effective as tamoxifen in preventing breast cancer in post-menopausal women, but with fewer side effects. Overall, these findings open a new horizon for SERMs as a class of drug which can not only be used for therapy and prevention of breast cancer, but also for various other diseases and disorders. We will provide a basic background of anti-estrogens, the current utility of the two pioneering SERMs tamoxifen and raloxifene, discuss in detail the putative mechanism of action of SERMs, and consider progress with new SERMs.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.